|
Dear Translation & Clinical Science and Discovery & Preclinical Research Communities (Formerly Biomarkers and Precision Medicine), With multi-parameter biomarker platforms such as NULISA and Olink becoming increasingly mainstream, questions regarding the appropriate level of validation are becoming ...
|